TH 9121

Drug Profile

TH 9121

Alternative Names: TH9121

Latest Information Update: 19 Mar 2007

Price : $50

At a glance

  • Originator Baker Medical Research Institute; Nonindustrial source
  • Developer Nonindustrial source
  • Class Anti-ischaemics; Antiarrhythmics
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias; Myocardial ischaemia

Most Recent Events

  • 03 Oct 1997 Preclinical development for Myocardial ischaemia in Australia (unspecified route)
  • 03 Oct 1997 Preclinical development for Arrhythmias in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top